ArticleOncogene2001
Development of mammary adenocarcinomas by tissue-specific knockout of Brca2 in mice.
Article in Oncogene, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 110 citations in OpenAlex.
- Insights from three decades of BRCA1/2 modeling in mice.Nature genetics · 2026Review
- G-quadruplexes as a source of vulnerability in BRCA2Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- BRCA2 reversion mutation-independent resistance to PARP inhibition through impaired DNA prereplication complex function.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Facing the Challenge to Mimic Breast Cancer Heterogeneity: Established and Emerging Experimental Preclinical Models Integrated with Omics Technologies.International journal of molecular sciences · 2025Review
- BRCA2 promotes genomic integrity and therapy resistance primarily through its role in homology-directed repair.Molecular cell · 2024Article
- Loss of the BRCA1-PALB2 interaction accelerates p53-associated tumor development in mice.Genes & diseases · 2022Article
- Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development.NPJ breast cancer · 2021Article
- Advances in Rodent Models for Breast Cancer Formation, Progression, and Therapeutic Testing.Frontiers in oncology · 2021Review
- CD200 promotes immunosuppression in the pancreatic tumor microenvironment.Journal for immunotherapy of cancer · 2020Article
- Mouse ER+/PIK3CAOncogene · 2019Article
- Article
- Evidence of Intertissue Differences in the DNA Damage Response and the Pro-oncogenic Role of NF-κB in Mice with Disengaged BRCA1-PALB2 Interaction.Cancer research · 2018Article
- Article
- BRCA2 suppresses replication stress-induced mitotic and G1 abnormalities through homologous recombination.Nature communications · 2017Article
- The DNA resection protein CtIP promotes mammary tumorigenesis.Oncotarget · 2016Article
- Wip1 phosphatase in breast cancer.Oncogene · 2015Review
- Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.Cancer cell · 2015Article
- Brca2 deficiency leads to T cell loss and immune dysfunction.Molecules and cells · 2015Article
- Mouse models of breast cancer.Methods in molecular biology (Clifton, N.J.) · 2015Article
- Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer.Cancer discovery · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Cre-mediated deletion of exons 3 and 4 of the mouse Brca2 gene occurring specifically in mammary epithelial cells of conditional female mutants carrying a combination of loxP-modified and null Brca2 alleles resulted in a high incidence (77%) of breast tumors that were often palpable and developed in one or more glands after long latency (time for median tumor-free survival of approximately 1.4 years; total of 40 tumors in 20 animals). These invasive adenocarcinomas were histologically quite uniform, exhibiting predominantly a solid, nodular tumor pattern with very few variants, in striking contrast to the morphological heterogeneity of analogous Brca1-associated tumors. The karyotypes of tumor cells lacking Brca2 had various chromosomal aberrations and ranged from diploid to hypertetraploid, but this wide variability was incongruous with the histological appearance of carcinomas that was comparable between specimens. The implications of these observations in the context of models positing that Brca2 is involved in the maintenance of genomic stability are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.